1. Home
  2. RAVE vs LITS Comparison

RAVE vs LITS Comparison

Compare RAVE & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rave Restaurant Group Inc.

RAVE

Rave Restaurant Group Inc.

N/A

Current Price

$2.59

Market Cap

40.1M

ML Signal

N/A

LITS

Lite Strategy Inc.

N/A

Current Price

$1.15

Market Cap

40.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RAVE
LITS
Founded
1958
2000
Country
United States
United States
Employees
N/A
4
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
40.1M
40.8M
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
RAVE
LITS
Price
$2.59
$1.15
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
24.6K
302.5K
Earning Date
05-25-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
11.76
N/A
EPS
0.09
N/A
Revenue
$15,120,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$29.78
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.01
$0.95
52 Week High
$3.75
$3.03

Technical Indicators

Market Signals
Indicator
RAVE
LITS
Relative Strength Index (RSI) 37.26 52.46
Support Level $2.34 $1.17
Resistance Level $3.21 $1.65
Average True Range (ATR) 0.13 0.07
MACD -0.02 0.02
Stochastic Oscillator 39.32 83.91

Price Performance

Historical Comparison
RAVE
LITS

About RAVE Rave Restaurant Group Inc.

Rave Restaurant Group Inc operates and franchises pizza buffet, delivery/carry-out, express restaurants, and ghost kitchens. It operates restaurants under the brand name, Pizza Inn, and Pie Five Pizza Company. It has three operating segments. The Pizza Inn Franchising and Pie Five Franchising segments establish franchisees, licensees, and territorial rights. The corporate administration and other segments. The Pizza Inn Franchising segment accounts for the majority of the company's revenue. Geographically, it generates the majority of the revenue from the United States.

About LITS Lite Strategy Inc.

Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.

Share on Social Networks: